Aqualung Therapeutics

About:

Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.

Website: https://www.aqualungtherapeutics.com/

Top Investors: National Institutes of Health, Florida Opportunity Fund, National Institute for Health Research, JSR Life Sciences

Description:

Aqualung Therapeutics (Aqualung Therapeutics Corporation) leadership are experienced academic leaders, entrepreneurs and translational scientists with expertise in Precision Medicine, who are exploring NAMPT as a key target and novel diagnostic in acute and chronic lung inflammatory disorders. As an organization they are committed to finding novel targets in the treatment of respiratory diseases. Their team is highly skilled at clinical development and they are working collaboratively with the FDA to ensure both acute and chronic respiratory diseases that have significant unmet medical need receive priority review.